JPH02154696A - 新規キメラ抗体 - Google Patents

新規キメラ抗体

Info

Publication number
JPH02154696A
JPH02154696A JP64000043A JP4389A JPH02154696A JP H02154696 A JPH02154696 A JP H02154696A JP 64000043 A JP64000043 A JP 64000043A JP 4389 A JP4389 A JP 4389A JP H02154696 A JPH02154696 A JP H02154696A
Authority
JP
Japan
Prior art keywords
formula
monoclonal antibody
dna
chimeric monoclonal
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP64000043A
Other languages
English (en)
Japanese (ja)
Inventor
Norman Dr Hardman
ノーマン　ハードマン
Laura Lee Dr Gill
ローラ　リー　ギル
Winter Ronald F J Dr De
ロナルド　エフ．ジェイ．デ　ウィンター
Kathrin Wagner
カトリン　バグナー
Christoph Dr Heusser
クリストフ　ホイサー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888800077A external-priority patent/GB8800077D0/en
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of JPH02154696A publication Critical patent/JPH02154696A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP64000043A 1988-01-05 1989-01-04 新規キメラ抗体 Pending JPH02154696A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8800077 1988-01-05
GB888800077A GB8800077D0 (en) 1988-01-05 1988-01-05 Novel chimeric antibodies
GB888820099A GB8820099D0 (en) 1988-01-05 1988-08-24 Novel chimeric antibodies
GB8820099.3 1988-08-24

Publications (1)

Publication Number Publication Date
JPH02154696A true JPH02154696A (ja) 1990-06-14

Family

ID=26293262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP64000043A Pending JPH02154696A (ja) 1988-01-05 1989-01-04 新規キメラ抗体

Country Status (10)

Country Link
EP (1) EP0323806B1 (enExample)
JP (1) JPH02154696A (enExample)
AU (1) AU625613B2 (enExample)
DE (1) DE3879452T2 (enExample)
DK (1) DK172444B1 (enExample)
ES (1) ES2053810T3 (enExample)
GR (1) GR3007853T3 (enExample)
HK (1) HK156695A (enExample)
IE (1) IE62440B1 (enExample)
PT (1) PT89384B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02231567A (ja) * 1989-01-10 1990-09-13 Boehringer Mannheim Gmbh 血清又は血液中の物質を診断検出する方法
US7803372B2 (en) 2002-10-08 2010-09-28 Immunomedics, Inc. Antibody therapy
JP2012515746A (ja) * 2009-01-21 2012-07-12 モノクローナル アンチボディーズ セラピューティックス 抗ｃｄ１６０モノクローナル抗体及びその使用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617127A1 (en) * 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigenic epitopes on B cell-bound IgE Immunoglobulins
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5081235A (en) * 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0486526B2 (en) 1989-08-07 2001-03-07 Peptech Limited Tumour necrosis factor binding ligands
CA2022959C (en) * 1989-08-10 2001-03-20 Hiroaki Maeda Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
EP0457875A4 (en) * 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69127749T2 (de) * 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
AU707440B2 (en) 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AU4373197A (en) * 1996-09-19 1998-04-14 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
EP1598671A1 (en) * 1999-10-28 2005-11-23 Agensys, Inc. Diagnosis and therapy of cancer using SGP28-related molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02231567A (ja) * 1989-01-10 1990-09-13 Boehringer Mannheim Gmbh 血清又は血液中の物質を診断検出する方法
US7803372B2 (en) 2002-10-08 2010-09-28 Immunomedics, Inc. Antibody therapy
JP2012515746A (ja) * 2009-01-21 2012-07-12 モノクローナル アンチボディーズ セラピューティックス 抗ｃｄ１６０モノクローナル抗体及びその使用

Also Published As

Publication number Publication date
PT89384B (pt) 1993-09-30
PT89384A (pt) 1990-02-08
AU625613B2 (en) 1992-07-16
EP0323806B1 (en) 1993-03-17
EP0323806A1 (en) 1989-07-12
DK2189A (da) 1989-07-06
IE62440B1 (en) 1995-02-08
ES2053810T3 (es) 1994-08-01
DE3879452D1 (de) 1993-04-22
IE890019L (en) 1989-07-05
HK156695A (en) 1995-10-13
DK2189D0 (da) 1989-01-04
DK172444B1 (da) 1998-07-27
GR3007853T3 (enExample) 1993-08-31
AU2759588A (en) 1989-07-06
DE3879452T2 (de) 1993-07-15

Similar Documents

Publication Publication Date Title
US5843708A (en) Chimeric antibodies
US6020153A (en) Chimeric antibodies
EP0323806B1 (en) Novel chimeric antibodies
US5705154A (en) Humanized monoclonal antibodies against human interleukin-4
EP0314161A1 (en) Human immunoglobulines produced by recombinant DNA techniques
JP2008195724A (ja) ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体
AU673347B2 (en) Genetically engineered antibodies
US5597710A (en) Humanized monoclonal antibodies against human interleukin-4
TW202611086A (zh) 特異性結合Claudin 18.2的抗體及其製法和應用
ES2282238T3 (es) Anticuerpos monoclonales contra el receptor ldl humano, su produccion y uso.
EP0396505A2 (en) Monoclonal antibodies specific for an immunoglobulin isotype
CN109879966B (zh) 基于鼠源cd19抗体的人源化设计及表达验证
CA2071305A1 (en) Anti-hiv antibodies
CN114213542B (zh) Cps-i抗体及其用途
CN113321730B (zh) Cldn18.2抗体及其应用
JP4028925B2 (ja) モノクローナル抗体
CN1817906B (zh) 抗人副甲状腺激素相关蛋白的抗体
JP2025523375A (ja) クローディン１８．２抗体、その製造方法及び使用
JPH104962A (ja) モノクローナル抗体及びその産生細胞
JPWO1996022309A1 (ja) 抗ｔｐｏモノクローナル抗体